Michael Yee
Stock Analyst at Jefferies
(3.15)
# 1,185
Out of 5,067 analysts
78
Total ratings
45.28%
Success rate
14.11%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALXO ALX Oncology Holdings | Upgrades: Buy | $2 → $3 | $1.51 | +98.68% | 5 | Mar 6, 2025 | |
| KOD Kodiak Sciences | Upgrades: Buy | $20 | $21.87 | -8.55% | 3 | Dec 9, 2024 | |
| BIIB Biogen | Downgrades: Hold | $250 → $180 | $176.82 | +1.80% | 5 | Dec 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $500 → $550 | $424.00 | +29.72% | 4 | Dec 9, 2024 | |
| AMGN Amgen | Maintains: Buy | $380 | $334.30 | +13.67% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $18.93 | +137.72% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $24.15 | +127.74% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $31.24 | +12.04% | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $40 | $29.87 | +33.91% | 1 | Sep 13, 2024 | |
| AXON Axon Enterprise | Initiates: Buy | $385 | $524.60 | -26.61% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1.4 → $10 | $7.41 | +34.95% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $7.49 | -59.95% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $30 | $23.62 | +27.01% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $15.88 | +25.94% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $41.79 | -52.14% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $9.52 | +688.23% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $9.95 | +201.51% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $38.69 | +68.00% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,875 → $1,125 | $8.61 | +12,966.20% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $3.17 | +846.37% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $10.40 | +188.46% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $37.93 | +216.37% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $17.11 | +338.34% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $81.01 | -62.97% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $26.93 | +185.93% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $125.27 | - | 3 | Jan 26, 2018 |
ALX Oncology Holdings
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $1.51
Upside: +98.68%
Kodiak Sciences
Dec 9, 2024
Upgrades: Buy
Price Target: $20
Current: $21.87
Upside: -8.55%
Biogen
Dec 9, 2024
Downgrades: Hold
Price Target: $250 → $180
Current: $176.82
Upside: +1.80%
Vertex Pharmaceuticals
Dec 9, 2024
Upgrades: Buy
Price Target: $500 → $550
Current: $424.00
Upside: +29.72%
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $334.30
Upside: +13.67%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $18.93
Upside: +137.72%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $24.15
Upside: +127.74%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $31.24
Upside: +12.04%
Oruka Therapeutics
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $29.87
Upside: +33.91%
Axon Enterprise
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $524.60
Upside: -26.61%
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $7.41
Upside: +34.95%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $7.49
Upside: -59.95%
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $23.62
Upside: +27.01%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $15.88
Upside: +25.94%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $41.79
Upside: -52.14%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $9.52
Upside: +688.23%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $9.95
Upside: +201.51%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $38.69
Upside: +68.00%
Mar 2, 2021
Downgrades: Hold
Price Target: $1,875 → $1,125
Current: $8.61
Upside: +12,966.20%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $3.17
Upside: +846.37%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $10.40
Upside: +188.46%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $37.93
Upside: +216.37%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $17.11
Upside: +338.34%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $81.01
Upside: -62.97%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $26.93
Upside: +185.93%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $125.27
Upside: -